DRUG RESISTANT MALARIA
  • Literally speaking, drug resistant malaria means malaria caused by a plasmodium resistant to usual antimalarial drugs.
  • Although chloroquine resistant strains of P. vivax have been described, drug resistance poses a serious clinical problem only with P. falciparum, which accounts for over 70% of cases and much of the mortality of human malaria.
Global Scenario of Drug Resistant Malaria
P. falciparum resistance
  • Chloroquine resistant strains of P. falciparum are found now in nearly all areas of chloroquine use including South America, Central America east of the Panama Canal, the Western Pacific, East Asia and many regions of Africa south of the Sahara.
  • Resistance to the combination of pyrimethamine and sulfadoxine is prevalent in some areas of Southeast Asia, the Amazon Basin of South America and many foci in sub-Saharan Africa.
  • Variable degrees of decreased responsiveness to quinine and quinidine have been reported, though rarely, in Southeast Asia and Oceania and apparently in sub-Saharan Africa
P. vivax resistance
  • Recent reports from Indonesia (Irian Jaya, Sumatra) and Papua New Guinea indicate high levels of P. vivax schizonts resistant to chloroquine. Decreased susceptibility may also be appearing in the Solomon Islands, Myanmar, Brazil, Colombia.
  • Resistance of P. vivax blood schizonts to pyrimethamine and sulfadoxine has been reported in many areas of the world, particularly Southeast Asia.
 
P. ovale and P. malariae resistance
  • P. ovale and P. malariae forms have not shown resistance to chloroquine
 
Indian Scenario of Drug Resistant Malaria
  • Of the two plasmodia which cause malaria in India, incidence of drug resistance is more common with P. falciparum.
  • Occasionally, P. vivax may also be drug resistant and this occurs specially as a result of improper treatment and inadequate dosage.
  • Originally, both the Plasmodia - vivax and falciparum - were sensitive to chloroquine, but, in recent years, more and more P. falciparum are developing resistance against chloroquine.
  • To overcome this problem of chloroquine resistance, Sulfadoxine + Pyrimethamine combination was used. But, very soon, some strains of falciparum developed resistance to this combination also.
  • P. falciparum resistant to traditional drugs like Quinine have also been reported.
  • Incidence in India will be difficult to know because in many cases it may not be recorded.
  • In India, the first confirmed report of chloroquine resistance in P. falciparum was reported in Diphu area of Karbianglong district of Assam in 1973.
  • A study carried out by the Clinical Pharmacological and Research Services Unit, in KEM hospital in Mumbai, confirmed the existence of chloroquine resistance in P. falciparum cases in Mumbai, incidence being 5% to full dose chloroquine.
  • Resurgence of P. falciparum resistant to chloroquine has been noticed in several regions of India. Earlier reports indicated chloroquine resistance to P. falciparum in North Eastern parts of the country with new foci of drug resistance being added.
However for all practical purposes, drug resistant malaria in the Indian context means malaria caused by strains of P. falciparum which are resistant to chloroquine.
Types of Drug Resistance
  • In defining criteria for resistance to the aminoquinoline antimalarial drugs, the WHO has described three grades of resistance following treatment
  • (Low grade) R1 : Recrudescence of infection between 7 and 28 days of completing treatment following initial resolution of symptoms and parasite clearance.
  • (High grade) R2 : Reduction of parasitaemia by > 75% at 48 hours but failure to clear parasites within 7 days.
  • R3 : Parasitaemia does not fall by >75% within 48 hours.
Causes of Drug Resistance
  • Resistance occurs most commonly due to improper treatment and inadequate dosage of antimalarial.
  • The possible mechanisms of development of resistance are as follows:
    i. Parasite does not allow the entry of drug.
    ii. After entry of drug, the malarial parasite does not retain it and throws it out.
    iii. May be a combination of both.
TOPdownload as PDF
 
 
 
 
 
 
 
 
 
 
 
 
 
Supported by Ipca Laboratories Ltd.  Leaders in Antimalarials  
designed & developed by
Aniktantra